Biocon will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia
NUFYMCO BLA has been approved by the USFDA
The company also reported significant progress toward its internally defined Sustainable Development Goals
Using a combination of blood and faecal samples, the service examines key biomarkers, including hereditary genetic status
Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s Semaglutide injection for weight management
The company along with its subsidiaries has overall bed capacity of 8800+ beds as on 30th September, 2025
Healthcare and insurance are not parallel systems; they are interdependent pillars of patient trust
UK headquartered digital health scale-up strengthens global tech and innovation footprint in the country
FOP is a rare genetic disorder caused by mutations in the ALK2 kinase
Xeureka will receive an upfront payment from UBE and will be eligible for milestone payments tied to future research progress
Subscribe To Our Newsletter & Stay Updated
